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Introduction 
Hepatitis C virus infection (HCV) represents a 
significant public health burden and infects 
approximately 185 million individuals worldwide. 
It is a leading cause of chronic liver disease, 
which can evolve to cirrhosis in 15% to 20% of 
those infected within 20 years, resulting in 
severe outcomes such as end-stage liver 
disease and hepatocellular carcinoma (1). It is the 
primary reason for liver transplantation in Europe 
and the United States (2). There are seven HCV 
genotypes with marked differences in global 
geographic distribution and susceptibility to 
antiviral therapy (3). Since the discovery of HCV 
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in 1989, there have been numerous advances in 
medical therapies available for the treatment of 
HCV infection. The main aim of antiviral 
treatment is to eradicate the virus, defined as a 
sustained virologic response (SVR), which 
means undetectable levels of plasma HCV RNA 
for 12 to 24 weeks after completion of therapy (4). 
SVR is associated with decreases in all-cause 
mortality, liver-related death rates and 
complications, and hepatocellular cancer rates 
(5, 6). The first agents available for treatment of 
HCV were the alfa interferons which resulted in 
SVR rates of approximately 15% (7). The 
combination of interferon (IFN) and ribavirin 
(RBV) improved SVR rates to 41% for 48-week 
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treatment regimens (8). With the introduction of 
pegylated-interferon (Peg-IFN), SVR rates 
increased to 50% (9). Besides its limited 
effectiveness, the combination of Peg-IFN and 
ribavirin was associated with long treatment 
duration and frequent and severe adverse 
effects, but remained the standard of care for 
over a decade. The introduction of direct-acting 
antivirals (DAAs) has revolutionized therapeutic 
options for HCV infection (10). The first two 
approved drugs were boceprevir and telaprevir, 
NS3/4A protease inhibitors, used in combination 
with traditional dual therapy (11, 12). This strategy 
managed to increase the rates of SVR to 70% (10-
12), but with greater toxicity, an increased pill 
burden, drug-drug interactions, low barriers to 
resistance, and notable side effects (13-15). Since 
2013, and the introduction of new, more effective 
DAAs with pan-genomic properties and 
excellent tolerance, the treatment of HCV has 
had a new scenario: increased rates of SVR (even 
up to 100%), shorter therapy duration and less 
toxicity (16). 
Direct-acting antivirals 
 Currently available DAAs are classified into four 
categories based on their mechanism of action: 
non-structural 3/4A serine protease inhibitors, 
non-structural 5A inhibitors, nucleotide 
analogue inhibitors of the non-structural 5B 
polymerase and non-nucleoside inhibitors of the 
non-structural 5B polymerase (17, 18). These 
drugs target the replication, polyprotein 
processing, packaging in nucleocapsid, 
assembly, and release of HCV infectious 
particles (3). Mutations at different positions in 
the NS3 protease, NS5B5 polymerase and NS5A 
protein affect viral susceptibility and the 
outcome of DAA-based therapies. However, the 
high specificity of DAAs makes them sensitive to 
small changes in the viral sequence responsible 
for antiviral resistance (10). Different currently 
approved interferon-free combination therapies 
with DAAs provide synergistic antiviral potency 
and prevent the development of DAAs 
resistance (19). 
First-generation NS3/4A protease inhibitors 
The NS3/4A protease is involved in post-
translational processing and releasing of the 
NS3, NS4A, NS4B, NS5A and NS5B from the HCV 
polyprotein (20), and it is critical for replication of 
the virus (21). In 2011, the first generation of 
NS3/4A inhibitors (boceprevir and telaprevir) 
was specific for the treatment of chronic 
hepatitis C, genotype 1, and was used in 
combination with PegINF and RBV. The 
mechanism of action is the forming of a 
reversible covalent bond with the NS3/4A active 
site. Limitations to the triple therapy for CHC 
included adverse effects such as 
gastrointestinal issues, skin reactions and bone 
marrow toxicity, and low barriers to resistance 
(22). Also, boceprevir and telaprevir are potent 
cytochrome p-150 inhibitors, resulting in 
significant drug-drug interaction (12). 
Second-generation protease inhibitors 
Second-wave protease inhibitors offer several 
advantages over the first generation: improved 
pharmacokinetics, which allows a once-a-day 
dosing schedule, more tolerable side-effects, 
and fewer drug-drug interactions (23). 
NS5A inhibitors 
Because of its critical involvement in viral 
replication and assembly (27), NS5A has been 
identified as a target for viral inhibition. Inhibition 
of NS5A at picomolar concentrations has been 
associated with significant reductions in HCV 
RNA levels in cell culture-based models (28, 29). 
NS5A inhibitors have pan-genotypic activity. 
Synergistic inhibition of viral production and an 
increased barrier to resistance (30) have been 
accomplished with the use of multiple DAAs, 
including an NS5A inhibitor, in cell culture. The 
exact mechanism of antiviral action of NS5A 
inhibitors is unknown, and its detailed function 
remains unclear. Available evidence suggests 
that they have multiple effects, interfering with 
several functions of NS5A in the HCV life cycle, 
and disrupt the establishment of replication sites 
(31). NS5A inhibitors are daclatasvir, ombitasvir, 
ledipasvir, elbasvir, and velpatasvir. 
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Polymerase NS5B inhibitors 
NS5B is the RNA-dependent RNA polymerase, 
and it is next reasonable target for the treatment 
of HCV. NS5B inhibitors can be classified into 
non-nucleotide inhibitors (NNIs) and nucleotide 
inhibitors (NIs) (32), both of them binding to the 
NS5B polymerase to terminate replication of the 
virus. NS5B utilizes the HCV RNA genome as a 
template for RNA synthesis. Nucleoside 
analogue inhibitors incorporate into the HCV 
RNA chain leading to chain termination. Because 
of that, NS5B inhibitors commonly show pan-
genotypic activity with a high barrier to 
resistance. They are commonly used in 
combination with other classes with higher 
barriers to resistance. The most used NS5B 
inhibitors are sofosbuvir, as a nucleoside 
analogue inhibitor (33), and dasabuvir, as an 
example of a non-nucleoside inhibitor. 
Currently available DAAs and 
treatment strategies 
A number of highly effective DAAs allow 
clinicians to customize HCV therapy according 
to HCV-genotype, liver fibrosis stage and 
previous treatment experience (34, 35). 
Commercialized DAAs approved by the United 
States Food and Drug Administration (FDA) (4) 
are listed in Table 1.  
Several factors must be taken into account 
when selecting the suitable therapeutic 
regimen. Clinically, it is necessary to evaluate 
Table 1. The list of currently available DAAs 
Medicine Brand name DAA class Dosing Genotypes 




400 mg (one pill) per 
day 
Genotypes 1, 2, 3, 4 
Simeprevir Olysio NS3/4A protease 
inhibitor 
 
150 mg (one 
capsule) per day 
Genotype 1 
 
Daclatasvir Daklinza NS5A protein 
inhibitor 
 
60 mg (two pills) 
once a day 




Harvoni NS5A inhibitor Sofosbuvir (400 mg) 
plus ledipasvir (90 
mg), in a single pill 
taken once per day 
 





Viekira NS5A inhibitor + 
NS3/4A protease 
inhibitor + CYP3A4 





12.5-75-250-50 mg Genotype 1 
Daclatasvir in 
combination with 
sofosbuvir +/ RBV  
 





60 mg once daily + 
sofosbuvir 400 mg 











400 mg of 
sofosbuvir and 100 
mg of velpatasvir 
once daily 
Genotypes 1-6  
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prior treatment history, the severity of the liver Table 2. Treatment strategies in Croatia 
Clinical parameters Treatment option 
Genotype 1 naive patients  
Mild fibrosis Peg IFN +RBV for 24-48 weeks. 
Advanced fibrosis Simeprevir/sofosbuvir and PeglFN + ribavirin. 
Significant fibrosis, contraindications to IFN therapy, 
presence of extrahepatic manifestations, HIV-
Coinfection, transplanted patients 
IFN-free regimens for 12 weeks: 
Ombitasvir, ritornavir-boosted paritaprevir, dasabuvir + 
ribavirin; 
Sofosbuvir and ledipasvir ± ribavirin; Sofosbuvir and 
simeprevir ± ribavirin. 
 
Decompensated cirrhosis Sofosbuvir and ledipasvir ± ribavirin for 24 weeks. 
Genotype 1 experienced patients   
Relapse or partial responders with F1-F3 PegIFN-α + RBV and simeprevir or sofosbuvir for 12 
weeks. 
 
Non-response (regardless of fibrosis); F4 fibrosis 
(regardless of type of response); TT IL-28B genotype; 
contraindications to IFN therapy; extrahepatic 
manifestations, HIV-coinfected and transplanted 
patients 
 
IFN-free regimens for 12 weeks: 
Ombitasvir, paritaprevir and ritonavir, dasabuvir ± 
ribavirin; 
Sofosbuvir and ledipasvir ± ribavirin; 
Sofosbuvir and simeprevir ± ribavirin. 
Decompensated cirrhosis Sofosbuvir and ledipasvir with ribavirin for 12 weeks, or 
24 weeks without ribavirin. 
 
Previously treated with PegIFN-α + RBV + PI Sofosbuvir + ledipasvir ± ribavirin for 12 weeks. 
Genotype 4 The same recommendations as for genotype 1, with 
the exception of fixed combination of ombitasvir, 
paritaprevir and ritonavir, which is used without 
dasabuvir. 
Genotype 2  
Treatment naive with F1-F3 fibrosis PegIFN-α and RBV for 24 weeks. 
Treatment naive with F4 fibrosis, treatment 
experienced regardless of fibrosis stage, 
contraindications to IFN, extrahepatic manifestations 
or HIV coinfected patients, transplanted patients 
 
Sofosbuvir and ribavirin for 12-20 weeks (depending on 
cirrhosis). 
Genotype 3  
Treatment naive with F1-F3 fibrosis Peg IFN and ribavirin for 24 weeks. 
Treatment naive with F4 fibrosis, treatment 
experienced 
PegIFN-α, RBV and sofosbuvir for 12 weeks. 
F1-F3 fibrosis, contraindication to IFN Sofosbuvir and ribavirin. 
F4 fibrosis, contraindication to IFN therapy Sofosbuvir, ledipasvir and ribavirin for 24 weeks or 
sofosbuvir, daclatasvir and ribavirin for 24 weeks. 
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disease, the degree of hepatic fibrosis, the 
presence of decompensation in patients with 
cirrhosis, renal function, the presence of 
extrahepatic manifestations of HCV, and the 
other medications the patient is taking. 
Virologically, it is necessary to know the 
genotype and its subtype, as well as to monitor 
the viral load at 12 to 24 weeks after therapy is 
completed and, in some cases, to determine the 
IL28B polymorphism or Q80K mutation (36, 37).  
The highest priority for treatment should be 
given to the patients with advanced fibrosis, 
compensated cirrhosis, severe extrahepatic 
hepatitis, as well as those on the active liver 
transplant waiting list, and liver transplant 
patients with recurrence of the infection. 
Patients with high priority for treatment are the 
non-responders to triple therapy or patients with 
extrahepatic manifestations of HCV. 
Independently of the disease status, treatment 
should also be considered for certain subgroups 
of HCV patients, such as patients at high risk of 
transmission or women of child-bearing age (34, 
35). 
HCV treatment in Croatia 
The prevalence of HCV in Croatia in the general 
population is low, with the estimated number of 
HCV patients around 39,000 (38, 39) and higher 
prevalence rates in prison populations, HIV 
patients, individuals with high-risk sexual 
behavior and alcohol abusers. Management of 
HCV infection in Croatia is following the 
European Association for the Study of the Liver 
(EASL) guidelines, Croatian Guidelines, and the 
recommendations of the Croatian Health 
Insurance Fund (HZZO). According to the 
recommendations, the highest priority is given to 
the patients with significant fibrosis or cirrhosis, 
extrahepatic manifestations, in patients with 
HCV recurrence after liver transplantation and in 
HBV/HCV and HIV/HCV-coinfected patients. 
Priority is also given to individuals at risk of 
transmitting HCV (injection drug users, people 
with high-risk sexual practices, women of child-
bearing age, haemodialysis patients). Treatment 
can be postponed in patients with no or mild 
liver fibrosis with no clinically significant 
extrahepatic manifestations. On the other hand, 
treatment is not recommended in patients with 
limited life expectancy (35-37, 40, 41). Available 
drugs covered directly by the Croatian Health 
Insurance Fund in 2016 are Peg IFN; ribavirin; 
simeprevir; sofosbuvir, ombitasvir + ritonavir-
boosted paritaprevir +/- dasabuvir; and 
sofosbuvir + ledipasvir. Treatment strategies for 
patients with different clinical parameters are 
listed in Table 2. 
Conclusion 
The appearance of direct-acting antiviral drugs 
has brought significant advances in the 
treatment of hepatitis C – high tolerability and 
convenient dosing of an all-oral regimen, 
reduced progression to cirrhosis and lower 
incidence of complications. With continuous 
screening and education, as well as timely 
detection, diagnose and treatment of HCV, 
reducing the prevalence and final eradication of 
the disease appears to be promising. 
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